Cancer-Derived Exosomal miR-651 as a Diagnostic Marker Restrains Cisplatin Resistance and Directly Targets ATG3 for Cervical Cancer

Figure 6

ATG3 as a direct target of miR-651 in cervical cancer. (a) Binding sites between miR-651 and wild-type or mutated ATG3. (b, c) Dual luciferase report for confirming the interactions between miR-651 and ATG3 in HeLa/S and HeLa/DDP cells. (d–f) ATG3 mRNA and protein expression in HeLa/S and HeLa/DDP cells transfected with miR-651 mimics or NC. (g–i) Expression of ATG3 mRNA and protein in HeLa/S and HeLa/DDP cells with miR-651 inhibitor or NC transfection. .

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)